
Inhibitor Of Apoptosis (IAP) Antagonist- Pipeline Insight, 2024
Description
Inhibitor Of Apoptosis (IAP) Antagonist- Pipeline Insight, 2024
DelveInsight’s, “Inhibitor Of Apoptosis (IAP) Antagonist- Pipeline Insight, 2024,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Inhibitor Of Apoptosis (IAP) Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Inhibitor Of Apoptosis (IAP) Antagonist: Overview
Inhibitors of Apoptosis (IAPs) are a family of proteins with various biological functions including regulation of innate immunity and inflammation, cell proliferation, cell migration and apoptosis. They are characterized by the presence of at least one N-terminal baculoviral IAP repeat (BIR) domain involved in protein-protein interaction. Inhibitor of apoptosis proteins (IAPs) is a class of key apoptosis regulators that promote cancer cell resistant to apoptosis, particularly in cancer treatment. Disrupting the binding of IAPs with their functional partners therefore is a promising strategy to restore the apoptotic response to proapoptotic stimuli, particularly those introduced by standard cancer therapies. Inhibitor of apoptosis proteins (IAPs) play a major role in determining whether cells undergo apoptosis in response to TNF as well as other stimuli. IAPs play a major role in influencing the production of multiple inflammatory mediators, arguing that these proteins are important regulators of inflammation in addition to apoptosis. Furthermore, small molecule IAP antagonists can modulate spontaneous as well as TNF-induced inflammatory responses, which may have implications for use of these agents in therapeutic settings. Defects in apoptosis regulation are one main cause of cancer development and may result from overexpression of anti-apoptotic proteins such as inhibitor of apoptosis proteins (IAPs). IAPs represent possible targets for specifically neutralizing therapy resistance mechanisms that lead to therapy failure and relapse. XIAP on one hand inhibits cell death execution by physical interaction with caspases and by causing their proteasomal degradation, on the other hand it also triggers survival signaling via the NFκB pathway thereby directly shifting the survival/death balance in cancer cells toward death resistance and NFκB-driven survival. The results from a plethora of preclinical studies, which demonstrate that XIAP-antagonists prove efficacy in enhancing drug- and radiotherapy-related cancer cell death and in specific cancer types even cause tumor remission are very promising. Therefore, in combination with diagnostic methods to identify patient subgroups that benefit from these novel compounds, XIAP-antagonists may be developed into highly efficient drugs in personalized medicine to overcome therapy resistance in cancer treatment.
""Inhibitor of Apoptosis (IAP) Antagonist- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Inhibitor of Apoptosis (IAP) Antagonist pipeline landscape is provided which includes the disease overview and Inhibitor of Apoptosis (IAP) Antagonist treatment guidelines. The assessment part of the report embraces, in depth Inhibitor of Apoptosis (IAP) Antagonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Inhibitor of Apoptosis (IAP) Antagonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Inhibitor of Apoptosis (IAP) Antagonist R&D. The therapies under development are focused on novel approaches to treat/improve Inhibitor of Apoptosis (IAP) Antagonist.
This segment of the Inhibitor of Apoptosis (IAP) Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Inhibitor of Apoptosis (IAP) Antagonist Emerging Drugs
- Xevinapant: Debiopharm/Merck
- ASTX 660: Astex Pharmaceuticals
Further product details are provided in the report……..
Inhibitor of Apoptosis (IAP) Antagonist: Therapeutic Assessment
This segment of the report provides insights about the different Inhibitor of Apoptosis (IAP) Antagonist drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Inhibitor Of Apoptosis (IAP) Antagonist
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Inhibitor of Apoptosis (IAP) Antagonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Inhibitor of Apoptosis (IAP) Antagonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Inhibitor of Apoptosis (IAP) Antagonist drugs.
Inhibitor of Apoptosis (IAP) Antagonist Report Insights
- Inhibitor Of Apoptosis (IAP) Antagonist Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Inhibitor of Apoptosis (IAP) Antagonist drugs?
- How many Inhibitor of Apoptosis (IAP) Antagonist drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Inhibitor of Apoptosis (IAP) Antagonist?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Inhibitor of Apoptosis (IAP) Antagonist therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Inhibitor of Apoptosis (IAP) Antagonist and their status?
- What are the key designations that have been granted to the emerging drugs?
- Merck & Co.
- Novartis Pharmaceuticals
- Astex Pharmaceuticals
- Ascentage Pharma Group Inc.
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Xevinapant
- LCL 161
- ASTX 660
- APG-1387
- TQB3728
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Inhibitor Of Apoptosis (IAP) Antagonist: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Inhibitor Of Apoptosis (IAP) Antagonist– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Xevinapant: Merck & Co.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- ASTX 660: Astex Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- TQB3728: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Inhibitor Of Apoptosis (IAP) Antagonist Key Companies
- Inhibitor Of Apoptosis (IAP) Antagonist Key Products
- Inhibitor Of Apoptosis (IAP) Antagonist- Unmet Needs
- Inhibitor Of Apoptosis (IAP) Antagonist- Market Drivers and Barriers
- Inhibitor Of Apoptosis (IAP) Antagonist- Future Perspectives and Conclusion
- Inhibitor Of Apoptosis (IAP) Antagonist Analyst Views
- Inhibitor Of Apoptosis (IAP) Antagonist Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.